Kawilarang Stella, Wiratnaya I Gede Eka, Yasa I Wayan Putu Sutirta, Budiana I Nyoman Gede
Udayana University Faculty of Medicine, Department of Biomedical Science, Bali, Indonesia.
Udayana University Faculty of Medicine, Department of Orthopedic and Traumatology, Bali, Indonesia.
Turk J Obstet Gynecol. 2025 Jun 4;22(2):163-169. doi: 10.4274/tjod.galenos.2025.57485.
To evaluate the efficacy of secretomes in restoring ovarian function in premature ovarian insufficiency (POI) in a mouse model, researchers emphasizing their potential as a novel, cell-free therapy. This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and included studies from four databases through December 2023. The bias risk was assessed using the tool for animal studies, which is Systematic Review Centre for Laboratory Animal Experimentation risk-of-bias. Outcomes, including the hormonal levels of estradiol (E2), anti-müllerian hormone (AMH), and follicle-stimulating hormone (FSH) were analyzed, with statistical comparisons made between the secretome-treated and control groups. Four studies encompassing sixty mice were included. The meta-analysis showed a significant increase in E2 levels in the secretome group [mean difference (MD)=37.45, 95% confidence interval (CI): 5.78 to 69.11; p=0.02]. No significant difference in AMH levels was observed; however, a sensitivity analysis resulted in the difference becoming statistically significant (MD=1.83, 95% CI: 0.95 to 2.71; p<0.0001). Moreover, the analysis revealed a significant reduction in FSH levels in the secretome group (MD=-36.80, 95% CI: -61.91 to -11.69; p=0.004) even after the sensitivity analysis. Our findings demonstrated enhanced outcomes with secretome therapy in the management of POI. Further research, particularly involving human subjects, is necessary to validate these findings.
为了评估分泌组在小鼠模型中恢复卵巢早衰（POI）卵巢功能的疗效，研究人员强调了其作为一种新型无细胞疗法的潜力。本系统评价和荟萃分析遵循了《系统评价和荟萃分析的首选报告项目2020》指南，并纳入了截至2023年12月来自四个数据库的研究。使用动物研究工具（即实验动物系统评价中心偏倚风险工具）评估偏倚风险。分析了包括雌二醇（E2）、抗苗勒管激素（AMH）和促卵泡生成素（FSH）在内的激素水平等结果，并对分泌组治疗组和对照组进行了统计学比较。纳入了四项研究，共60只小鼠。荟萃分析显示，分泌组的E2水平显著升高[平均差（MD）=37.45，95%置信区间（CI）：5.78至69.11；p=0.02]。未观察到AMH水平有显著差异；然而，敏感性分析导致该差异具有统计学意义（MD=1.83，95%CI：0.95至2.71；p<0.0001）。此外，分析显示，即使经过敏感性分析，分泌组的FSH水平也显著降低（MD=-36.80，95%CI：-61.91至-11.69；p=0.004）。我们的研究结果表明，分泌组疗法在POI管理方面取得了更好的效果。有必要进行进一步研究，特别是涉及人类受试者的研究，以验证这些发现。
